_1777370220974_847775619.png&w=48&q=75){kind=small}
FDA peptide panel includes RFK Jr. supporters
U.S. health officials are set to review the safety of several peptide drugs in an upcoming FDA meeting, with new panels including industry professionals such as clinics, pharmacists, and industry advocates who have financial ties to the peptide industry. These substances, promoted for muscle building and anti-aging, are often unapproved and sold online or through wellness clinics, despite safety concerns and limited human research. Previous panels primarily comprised academic experts who deemed many peptides too risky for patient use.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)